Press Releases

Experienced medical executive advances to permanent role following successful leadership as Interim CMO. SEATTLE and VANCOUVER, British Columbia, January 12, 2026 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that it has…

SEATTLE and VANCOUVER, British Columbia, December 17, 2025 (GLOBE NEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, announced today that the company will be hosting in-person one-on-one meetings coinciding with the 44th Annual J.P. Morgan…

SEATTLE and VANCOUVER, British Columbia, December 8, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that the company has issued inducement grants of stock options to Erik Atkisson, Chief Legal Officer,…

One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation. Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025. SEATTLE and VANCOUVER, British Columbia, November 6, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the…

120-Day Safety Update Submitted to FDA. ORCA-OL Long-Term Safety Trial Successfully Concluded. DSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns. SEATTLE and VANCOUVER, British Columbia, November 3, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as…